Why the study?
What are the clinical pharmacokinetics of heparin and how do they affect therapeutic dosing?
What are the clinical pharmacokinetics of heparin and how do they affect therapeutic dosing?
The review highlights the variability in heparin pharmacokinetics, particularly between PE and DVT patients, emphasizing the need for continuous monitoring of clotting times to guide dosing.
Answers are grounded in this paper and cite their sources.
Supports individualized heparin monitoring in PE versus DVT; extends pharmacokinetic observations but leaves open outcome benefits without prospective trials.
The pharmacokinetic literature regarding heparin is reviewed, and suggestions regarding the therapeutic use of this anticoagulant are provided. Various kinetic parameters for heparin have been reported, including half-life of pharmacological (anticoagulant) effects using in vitro clotting time tests, and half-life and clearance of heparin using assays of heparin activity. Heparin half-life is shorter, and clearance is greater, in patients with pulmonary emboli compared to patients with deep venous thrombosis. However, heparin infusion rates may be similar regardless of type of thromboembolic disease to achieve a given pharmacological endpoint. The difference in in vitro clotting time test responses among patients given similar amounts of heparin is a most significant variable in determining heparin dosing regimens, and makes continued monitoring of heparin dosage and the associated in vitro clotting time test response necessary for the rational use of this drug.
No takes yet. Share an insight, caveat, or question.
Ralph H. Raasch (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: